Does celecoxib improve the efficacy of chemotherapy for advanced non-small cell lung cancer?

作者：Hou, Leng-Chen; Huang, Fang; Xu, Hong-Bin^*

来源：British Journal of Clinical Pharmacology, 2016, 81(1): 23-32.

DOI：10.1111/bcp.12757

• celecoxib
• meta-analysis
• non-small cell lung cancer

AimsClinical trials have reported conflicting results about whether celecoxib plus chemotherapy improves outcomes over chemotherapy alone in patients with advanced non-small cell lung cancer. @@@ MethodsWe performed a meta-analysis comparing the primary and secondary endpoints of treatment with celecoxib plus chemotherapy vs. chemotherapy alone in patients with advanced non-small cell lung cancer. @@@ ResultsSix eligible trials (1181 patients) were selected from the 206 studies that were identified initially. A significant difference, favouring celecoxib plus chemotherapy over chemotherapy alone, was observed in the overall response rate [odds ratio (OR) 1.34; 95% confidence interval (CI) 1.08, 1.67; P=0.009). However, there was no difference in the 1-year survival rate (OR 1.08; 95% CI 0.86, 1.35; P=0.512), clinical benefit (OR 1.05; 95% CI 1.88, 1.25; P=0.613), complete response (OR 0.77; 95% CI 0.39, 1.51; P=0.446) or partial response (OR 1.22; 95% CI 0.92, 1.63; P=0.163). Toxicity did not differ significantly with the exception of the occurrence of leucopenia and thrombocytopenia. @@@ ConclusionsCelecoxib plus chemotherapy appeared to improve the overall response rate compared with chemotherapy alone in the treatment of patients with advanced non-small cell lung cancer. Further prospective randomized controlled trials are now needed.

• 出版日期2016-1
• 单位同济大学